Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: A randomized, open-label, two-period, comparative, crossover study

Abernethy, 1989, The pharmacokinetic profile of amlodipine, Am Heart J., 118, 1100, 10.1016/0002-8703(89)90834-X Meredith, 1992, Clinical pharmacokinetics of amlodipine, Clin Pharmacokinet., 22, 22, 10.2165/00003088-199222010-00003 Haria, 1995, Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease, Drugs, 50, 560, 10.2165/00003495-199550030-00009 Beresford, 1988, Metabolism and kinetics of amlodipine in man, Xenobiotica, 18, 245, 10.3109/00498258809041660 Walker, 1994, Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine, Xenobiotica, 24, 243, 10.3109/00498259409043236 Stopher, 1988, The metabolism and pharmacokinetics of amlodipine in humans and animals, J Cardiovasc Pharmacol., 12, S55, 10.1097/00005344-198812007-00012 Rentsch, 2002, The importance of stereoselective determination of drugs in the clinical laboratory, J Biochem Biophys Methods., 54, 1, 10.1016/S0165-022X(02)00124-0 Tucker, 2000, Chiral switches, Lancet, 355, 1085, 10.1016/S0140-6736(00)02047-X Agranat, 2002, Putting chirality to work: The strategy of chiral switches, Nat Rev Drug Discov., 1, 753, 10.1038/nrd915 Burke, 2002, Chirality: A blueprint for the future, Br J Anaesth, 88, 563, 10.1093/bja/88.4.563 Hutt, 2002, The development of single-isomer molecules: Why and how, CNS Spectr., 7, 14, 10.1017/S1092852900028558 Arrowsmith, 1986, Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents, J Med Chem., 29, 1696, 10.1021/jm00159a022 Goldmann, 1992, Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: A correction, J Med Chem., 35, 3341, 10.1021/jm00096a005 Zhang, 2002, Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine, J Cardiovasc Pharmacol, 39, 208, 10.1097/00005344-200202000-00007 Adik-Pathak, 2004, Chiral molecules in hypertension: Focus on S-amlodipine, J Assoc Physicians India, 52, 187 World Medical Association Declaration of Helsinki, 1989 European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization, 2002, Guideline for Good Clinical Practice [EMEA Web site] Park, 2004, Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine for mulations in healthy adult male Korean subjects, Clin Ther., 26, 715, 10.1016/S0149-2918(04)90071-9 Abad-Santos, 2005, Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study, Pharmacol Res., 151, 445, 10.1016/j.phrs.2004.11.006 Rogoza, 2000, Validation of AD UA-767 device for the self-measurement of blood pressure, Blood Press Monit, 5, 227, 10.1097/00126097-200008000-00006 Chow, 1992, Design and Analysis of Bioavailability and Bioequivalence Studies, 48 Schuirmann, 1987, A comparison of the two one-sided tests procedure and the power approach for assess ing the equivalence of average bioavailability, J Pharmacokinet Biopharm, 15, 657, 10.1007/BF01068419 Vincent, 2000, Lack of effect of grapefruit juice on the pharmacokinetics and pharma codynamics of amlodipine, Br J Clin Pharmacol, 50, 455, 10.1046/j.1365-2125.2000.00283.x Farolfi, 1999, On the determination of bioequivalence, Pharmacol Res., 39, 1, 10.1006/phrs.1998.0405 Food and Drug Administration, 1992 Committee for Proprietary Medicinal Products (CPMP) Working Party on the Efficacy of Medicinal Products, 2001 Food and Drug Administration of Korea (KFDA), 1996 2006 Meyer, 2001, United States Food and Drug Administration requirements for approval of generic drug products, J Clin Psychiatry, 62, 4